Description: Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Home Page: www.salariuspharma.com
SLRX Technical Analysis
2450 Holcombe Boulevard
Houston,
TX
77021
United States
Phone:
832 834 6992
Officers
| Name | Title |
|---|---|
| Mr. David J. Arthur M.B.A. | CEO, Pres & Director |
| Mr. Mark J. Rosenblum CPA | Exec. VP of Fin. & CFO |
| Dr. Nadeem Q. Mirza M.D., M.P.H. | Sr. VP of Clinical Devel. |
| Dr. Daniela Y. Santiesteban | Director of Targeted Protein Degradation Program |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2523 |
| Price-to-Sales TTM: | 18.1198 |
| IPO Date: | 2015-01-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |